Baghdadi, T. A., Rothe, M., Garrett-Mayer, E., Meric-Bernstam, F., Mileham, K. F., Mohajer, R., Ikpeazu, C., Akce, M., Gregory, A., Tenner, L. L., Wadlow, R. C., Alese, O. B., Dublis, S. A., Gill, D. M., Acoba, J. D., Gregory, A., Hinshaw, D. C., Grantham, G. N., Halabi, S., Schilsky, R. L. (2026). Tucatinib + subcutaneous (SC) trastuzumab (Tuc + Trast SC) in patients (pts) with solid tumors with ERBB2 alterations (alts): Results from the targeted agent and profiling utilization registry (TAPUR) study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.3104